source
- GSK launches $2.5 billion restructuring plan to fund late-stage pipeline and offset upcoming HIV drug patent lossGSK reported $2.4 billion in impairment charges for the second quarter and unveiled a three‑year restructuring designed to save roughly $2.5 billion. The company says the savings will be redirecte…
- Altimmune's pemvidutide cuts heavy drinking days in Phase 2 trialAltimmune reported that its experimental GLP-1/GIP injection pemvidutide achieved its primary and key secondary goals in a Phase 2 study of alcohol use disorder. The double-blind trial enrolled 10…